Registration 333-298621
S-4/A · 2026-11-04 · 0001193125-26-446390
Terms from the governing filing for this registration; not a claim that the offering is open today.
Company research
Talawar Tx Inc.
CIK 2140859Updated Nov 11, 2026
Filing activity
Latest filing
12 filings on record · EFFECT, 424B3, S-4/A, 425, S-4.
About the company
Talawar Therapeutics is a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent disease drivers in a single therapy, targeting pathways that work together for greater, more durable impact. Our lead program, TALA-125, is a novel anti-IL-13 x anti-IL-18 bispecific that combines two clinically validated, largely orthogonal mechanisms designed to shatter the current limitations of existing treatments - with broad applicability across first-line patients and those who have failed previous therapies. Talawar is the first company formed to develop and commercialize assets discovered by Khanda Therapeutics, L.P. For more information, visit www.talawartx.com.
Recent filings
Show 5 more recent filings
Offerings
Registration 333-298621
Filing attachments
tlwr-ex4_1.htm · S-4/A · 2026-10-05
Exhibit 4.1 TALAWAR TX INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK This Certifies that _____________________________________________ is the owner of________________________________________________ FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE OF $0.00001 PER SHARE, OF TALAWAR TX INC. (THE “COMPANY”) transferable on the books of the Company in person or by duly authorized attorney upon surrender of this certificate properly endorsed. This cer…
Read attachment ↗tlwr-ex99_1.htm · S-4 · 2026-08-28
EX-99.1 8 tlwr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CONSENT OF HOULIHAN CAPITAL, LLC We hereby consent to the inclusion of our opinion letter to the Board of Directors of JATT II Acquisition Corp (“JATT”) as an exhibit to the Registration Statement on Form S-4 as filed by JATT with the Securities and Exchange Commission, and to the references to our firm and such opinion in such Registration Statement. In giving such consent, we do not admit, and we disclaim, that we come within the ca…
Read attachment ↗d136998dex991.htm · 425 · 2026-06-29
EX-99.1 8 d136998dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases Oversubscribed $225 million concurrent private investment in public equity (“PIPE”) with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b proof-of-concept study data rea…
Read attachment ↗d136998dex992.htm · 425 · 2026-06-29
EX-99.2 9 d136998dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Corporate Presentation June 2026 Disclaimer and forward-looking statements This confidential presentation has been made available to you for informal purposes only with the consent of Talawar Tx Inc. (the “Company” or Talawar ) and JATT II Acquisition Corp (“JATT”) and has been prepared to assist interested parties in making their own evaluation wi th respect to a business combination between the Company and JATT and related transact…
Read attachment ↗